Drugs tested to stop COVID-19 pneumonia from getting worse
NCT ID NCT04581954
Summary
This trial tested two existing anti-inflammatory drugs, ruxolitinib and fostamatinib, to see if they could prevent hospitalized COVID-19 pneumonia patients from getting sicker. The goal was to stop patients' conditions from worsening to the point of needing a ventilator or other intensive support. The study involved 185 adults with mild-to-moderate pneumonia and measured whether the drugs reduced the rate of severe disease progression over 14 days.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
-
London North West University Healthcare
London, HA1 3UJ, United Kingdom
-
Royal Berkshire NHS Foundation Trust
Reading, RG1 5AN, United Kingdom
-
Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire Hospital
Sheffield, S10 2JF, United Kingdom
-
The Leeds Teaching Hospital - St James University Hospitals NHS Trust
Leeds, LS9 7TF, United Kingdom
Conditions
Explore the condition pages connected to this study.